The National Institute for Health and Care Excellence

Thousands eligible for new chronic heart failure treatment following NICE recommendation

Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...
National Institute for Health and Care Excellence

Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

There is a simple discount patient access scheme for mirvetuximab soravtansine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor

There is a simple discount patient access scheme for pirtobrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

Evidence-based recommendation on teplizumab (Tzield) for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes ...
National Institute for Health and Care Excellence

Browse guidance by topic

Browse guidance by topic Cancer Biliary tract cancers Bladder cancer Blood and bone marrow cancers Brain cancers Breast cancer Cervical cancer Colorectal cancer Complications of cancer Endometrial ...